Copyright © 2011 by the McGraw-Hill Companies, Inc. All...

18
Copyright © 2011 by the McGraw-Hill Companies, Inc. All rights reserved. McGraw-Hill/Irwin

Transcript of Copyright © 2011 by the McGraw-Hill Companies, Inc. All...

Page 1: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

Copyright © 2011 by the McGraw-Hill Companies, Inc. All rights reserved.McGraw-Hill/Irwin

Page 2: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

Copyright © 2011 by the McGraw-Hill Companies, Inc. All rights reserved.McGraw-Hill/Irwin

Chapter 6

Defining the Organization's

Strategic Direction

Page 3: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-3

• Genzyme was founded in 1981 by scientists studying genetically inherited enzyme diseases

• Adopted a very unusual strategy of developing drugs for rare diseases rather than “blockbuster” drugs.

• Smaller markets, but fewer competitors

• Requires less advertising, smaller sales force

• In 1983, the FDA established the “Orphan Drug Act,” giving seven years market exclusivity to developers of drugs for rare (<200,000 patients) diseases.

• Also chose unusual strategy of doing its own manufacturing and sales rather than licensing to a pharmaceutical company.

• Diversified into side businesses to fund its R&D.

• By 2009, was one of the world’s largest biotech companies with 10,000 employees in 40 countries.

Genzyme’s Focus on

“Orphan Drugs”

Page 4: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-4

Discussion Questions:

1. How does Genzyme’s focus on orphan drugs affect the

degree of competition it faces? How does it affect the

bargaining power of customers?

2. How does focusing on orphan drugs affect the types of

resources and capabilities a biotech firm needs to be

successful?

3. Does Genzyme’s focus on orphan drugs make sense?

Do you think Genzyme has a long-term strategic intent?

4. Why do you think Genzyme has diversified into other

areas of medicine? What are the advantages and

disadvantages of this?

5. What recommendations would you offer Genzyme for

the future?

Genzyme’s Focus on

“Orphan Drugs”

Page 5: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-5

Overview

• A coherent technological innovation

strategy leverages the firm’s existing

competitive position and provides

direction for future development of the

firm.

• Formulating this strategy requires:

• Appraising the firm’s environment,

• Appraising the firm’s strengths, weaknesses,

competitive advantages, and core

competencies,

• Articulating an ambitious strategic intent.

Page 6: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-6

Assessing the Firm’s Current

Position

• External Analysis

• Two common methods are Porter’s Five-Force Model and Stakeholder Analysis.

• Porter’s Five-Force Model

1. Degree of existing rivalry. Determined by number of firms, relative size, degree of differentiation between firms, demand conditions, exit barriers.

2. Threat of potential entrants. Determined by attractiveness of industry, height of entry barriers (e.g., start-up costs, brand loyalty, regulation, etc.)

3. Bargaining power of suppliers. Determined by number of suppliers and their degree of differentiation, the portion of a firm’s inputs obtained from a particular supplier, the portion of a supplier’s sales sold to a particular firm, switching costs, and potential for vertical integration.

Page 7: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-7

Assessing the Firm’s Current

Position

4. Bargaining power of buyers. Determined by number of

buyers, the firm’s degree of differentiation, the portion of

a firm’s inputs sold to a particular buyer, the portion of a

buyer’s purchases bought from a particular firm,

switching costs, and potential for vertical integration.

5. Threat of substitutes. Determined by number of

potential substitutes, their closeness in function and

relative price.

Recently Porter has acknowledged the role of complements.

Must consider:

a) how important complements are in the industry,

b) whether complements are differentially available

for the products of various rivals (impacting the

attractiveness of their goods), and

c) who captures the value offered by the

complements.

Page 8: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-8

Assessing the Firm’s Current

Position

• Five-Force Model

Page 9: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-9

Assessing the Firm’s Current

Position

Stakeholder Analysis

1. Who are the stakeholders.

2. What does each stakeholder want.

3. What resources do they contribute to

the organization.

4. What claims are they likely to make

on the organization.

Page 10: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-10

Assessing the Firm’s Current

Position

• Internal Analysis

1. Identify the firm’s strengths and

weaknesses. Helpful to consider each

element of value chain.

Page 11: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-11

2. Assess which strengths have potential to be

sustainable competitive advantage

• Rare

• Valuable

• Durable

• Inimitable

• Resources are difficult (or impossible) to imitate when they are:

• Tacit

• Path dependent

• Socially complex

• Causally ambiguous

Assessing the Firm’s Current

Position

Competitive

Advantage Sustainable

Competitive

Advantage

Page 12: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-12

Identifying Core

Competencies and Capabilities

• Core Competencies: A set of integrated and harmonized abilities that distinguish the firm in the marketplace.

• Competencies typically combine multiple kinds of abilities.

• Several core competencies may underlie a business unit.

• Several business units may draw from same competency.

• Core competencies should:

• Be a significant source of competitive differentiation

• Cover a range of businesses

• Be hard for competitors to imitate

Page 13: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-13

Identifying Core

Competencies and Capabilities

Page 14: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-14

Identifying the Firm’s Core Competencies

• Gallon, Stillman and Coates offer a step-by-step

program for identifying core competencies.

• Module 1 -- Assemble a steering committee, appoint a

program manager, and communicate the overall goals of the

project to all members of the firm.

• Module 2 -- Constructing an inventory of capabilities

categorized by type. Assess their strength, importance, and

criticality.

• Module 3 – Organize capabilities by both their criticality and

the current level of expertise within the firm for each.

• Module 4 – Distill competencies into possible candidates for

the firm to focus on. No options should be thrown out yet.

• Module 5 -- Testing the candidate core competencies against

Prahalad and Hamel's original criteria.

• Module 6 -- Evaluate the firm’s position in the core

competency.

Research Brief

Page 15: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-15

Risk of Core Rigidities

• When firms excel at an activity, they can become over committed to it and rigid.

• Incentives and culture may reward current competencies while thwarting development of new competencies.

• Dynamic capabilities are competencies that enable the firm to quickly respond to change.

• E.g., firm may develop a set of abilities that enable it to rapidly deploy new product development teams for a new opportunity; firm may develop competency in working with alliance partners to gain needed resources quickly.

Page 16: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-16

Strategic Intent

• Strategic Intent

• A long-term goal that is ambitious, builds upon and stretches

firm’s core competencies, and draws from all levels of the

organization.

• Typically looks 10-20 years ahead, establishes clear milestones

• Firm should identify resources and capabilities needed to close

gap between strategic intent and current position.

Page 17: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-17

The Balanced Scorecard

Kaplan and Norton argue

that effective performance

measurement should

incorporate:

• Financial perspective

• Customer perspective

• Internal perspective

• Innovation and learning

Theory In Action

Page 18: Copyright © 2011 by the McGraw-Hill Companies, Inc. All ...contents.kocw.net/KOCW/document/2014/Hoseo/leejongwon4/6.pdf · •In 1983, the FDA established the “Orphan Drug Act,”

6-18

Discussion Questions

1. What is the difference between a strength, a competitive

advantage, and a sustainable competitive advantage?

2. What makes an ability (or set of abilities) a core competency?

3. Why is it necessary to perform an external and internal

analysis before the firm can identify its true core

competencies?

4. Pick a company you are familiar with. Can you identify some

of its core competencies?

5. How is the idea of “strategic intent” different from models of

strategy that emphasize achieving a fit between the firm’s

strategies and its current strengths, weaknesses, opportunities

and threats (SWOT)?

6. Can a strategic intent be too ambitious?